These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 39198847

  • 1. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.
    Liu J, Wang W, Wang K, Liu W, Zhao Y, Han X, Wang L, Jiang BH.
    J Transl Med; 2024 Aug 28; 22(1):793. PubMed ID: 39198847
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H, Xu L.
    Oncogene; 2018 Aug 28; 37(31):4300-4312. PubMed ID: 29717264
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC.
    Ther Adv Respir Dis; 2020 Aug 28; 14():1753466620915156. PubMed ID: 32552611
    [Abstract] [Full Text] [Related]

  • 4. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G.
    Lung Cancer; 2014 Feb 28; 83(2):146-53. PubMed ID: 24331411
    [Abstract] [Full Text] [Related]

  • 5. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

  • 6. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Dec 04; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 7. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P, Cao L, Chen X, Jing R, Yue W.
    BMC Cancer; 2019 Dec 10; 19(1):1203. PubMed ID: 31823748
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Lin YC, Lin YC, Shih JY, Huang WJ, Chao SW, Chang YL, Chen CC.
    Clin Cancer Res; 2015 Jan 15; 21(2):428-38. PubMed ID: 25593344
    [Abstract] [Full Text] [Related]

  • 10. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S, Im JH, Kim WK, Choi YJ, Lee JY, Kim SK, Kim SJ, Kwon SW, Kang KW.
    Oxid Med Cell Longev; 2021 Jan 15; 2021():5428364. PubMed ID: 34367462
    [Abstract] [Full Text] [Related]

  • 11. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
    Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, Du W, Zeng Y, Zhu J, Liu Z, Huang JA.
    J Hematol Oncol; 2020 Dec 07; 13(1):169. PubMed ID: 33287873
    [Abstract] [Full Text] [Related]

  • 12. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q, Wang Y, He J.
    J Clin Lab Anal; 2021 Jul 07; 35(7):e23853. PubMed ID: 34057242
    [Abstract] [Full Text] [Related]

  • 13. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, Fang JM, Chen CC.
    Oncogene; 2019 Jan 07; 38(4):455-468. PubMed ID: 30111817
    [Abstract] [Full Text] [Related]

  • 14. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P, Song H.
    Cell Physiol Biochem; 2018 Jan 07; 48(4):1505-1518. PubMed ID: 30071534
    [Abstract] [Full Text] [Related]

  • 15. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C, Cao H, Cui Y, Jin S, Gao W, Huang C, Guo R.
    Thorac Cancer; 2021 Oct 07; 12(19):2574-2584. PubMed ID: 34510760
    [Abstract] [Full Text] [Related]

  • 16. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
    Zhao L, Wang Y, Sun X, Zhang X, Simone N, He J.
    Int J Mol Sci; 2024 Feb 17; 25(4):. PubMed ID: 38397056
    [Abstract] [Full Text] [Related]

  • 17. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Feb 17; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 18. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan 17; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

  • 19. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
    Peng C, Li P, Yang M, Chen D, Huang Y.
    Zhongguo Fei Ai Za Zhi; 2021 Aug 20; 24(8):538-547. PubMed ID: 34334155
    [Abstract] [Full Text] [Related]

  • 20. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
    Wen Q, Jiao X, Kuang F, Hou B, Zhu Y, Guo W, Sun G, Ba Y, Yu D, Wang D, Zhang F, Qiao HC, Wang S, Tang S, Qiao H.
    EBioMedicine; 2019 Feb 20; 40():198-209. PubMed ID: 30738830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.